HEALTHJul 20 · 03:39 UTCDAWN[email protected] (Imran Ayub)

40 registered life-saving medicines remain out of patients’ reach

Around 40 life-saving medicines registered in Pakistan remain unavailable to patients due to delayed federal price approvals, forcing reliance on smuggled or unregistered drugs for conditions like cancer, diabetes, and haemophilia. The medicines, including Keytruda and Adalimumab, have completed regulatory processes but await price notifications since December 2024.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Drug Regulatory Authority of PakistanorganizationPakistan Chemists and Druggists AssociationorganizationPakistan Pharmaceutical Manufacturers AssociationorganizationKeytruda (Pembrolizumab)topicAdalimumabtopicAbdul Samad BuddanipersonPakistanplaceHumador insulintopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJul 19 · 05:12 UTC
At the pharmacy, poverty reveals itself in returned boxes, unfinished treatments
HEALTHJul 19 · 06:34 UTC
Drap urged to exempt 10cc syringes from ban
HEALTHJul 13 · 02:53 UTC
Pricing delay raises shortage of medicine, counterfeiting risks
HEALTHJun 12 · 21:45 UTC
STAT+: Trump administration revisits policy to close Medicare drug price negotiation loophole
HEALTHMay 4 · 17:34 UTC
Opinion: Mifepristone court ruling makes drug development riskier for everyone
HEALTHJul 1 · 07:55 UTC
‘Life-saving’ drug for people with opioid dependency to be pulled from Australia by end of year